RareResearch.AI
← Back to atlas

L723P

Category 3/4 — Most DruggablePathogenicLumenal · predictedσ-1 candidateEditorial
LeucineProline at position 723 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Leucine → Proline at position 723 in wolframin's C-terminal lumenal domain. ClinVar Pathogenic. AlphaMissense 0.959, DynaMut2 ΔΔG -0.19 kcal/mol (destabilising). Another proline-introduction variant in the lumenal fold.

Interactive 3D Structure

Wild-type reference
Wild-type L723 — hydrogen bond to I720
Fullscreen ↗
DynaMut2 mutant · L723P
Mutant P723 — hydrogen bond to I720 lost (2 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost2 gained3 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondI720I720Preserved
Polar contactA719Gained
Polar contactI720I720Preserved
Van der WaalsI720Gained
Van der WaalsN721Lost
HydrophobicI727I727Preserved
HydrophobicM731Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.19kcal/mol
Destabilising — mild
AlphaMissense
0.959
LPath
AlphaFold pLDDT
83
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Standard confidence · Lumenal

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, single submitter
Associated conditions(no specific conditions catalogued for L723P — ClinVar Pathogenic by review evidence)
InheritanceInheritance not specified. ClinVar Pathogenic.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2168T>C
ClinVar accessionVCV002203530
Last evaluated2024/12/16 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Classified for1★ unverified submission

ClinVar classifies this variant as Pathogenic, but does not state what it is classified for. ClinVar records the condition only as "not provided". A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
Absent from gnomAD v4
Homozygotes
Not available

No population breakdown — the variant is absent from gnomAD v4, so no ancestry group has an observed frequency.

No homozygotes — the variant is absent from gnomAD v4 altogether.

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 723 sits in wolframin's C-terminal lumenal domain. The AlphaFold model places L723 within 5 Å of MET722 (2.5 Å), PRO724 (2.5 Å), ILE720 (3.6 Å), ASN721 (4.6 Å), and ALA719 (4.8 Å). The local environment is hydrophobic-rich (M722, I720, A719) with a single polar residue (N721). Notably, PRO724 sits at 2.5 Å — the immediate downstream neighbor is already a proline.

Replacing L723 with proline introduces a second proline immediately adjacent to the existing P724 — a Pro-Pro motif is unusual and structurally distinctive. Two adjacent prolines create a particularly rigid backbone segment with restricted conformational options. The wild-type Leu-Pro motif at 723-724 transitions from flexible to constrained backbone; the variant Pro-Pro motif is constrained on both sides.

The |ΔΔG| of 0.19 is modest — the fold absorbs the new proline because the local environment was already constrained. But the geometry shifts: the Pro-Pro motif likely adopts a different local conformation than the wild-type Leu-Pro, and surrounding residues (M722, I720) rearrange to accommodate.

AlphaMissense's 0.959 score captures the functional severity — the shifted local geometry disrupts whatever interaction the wild-type Leu-Pro motif enabled.

Amino-acid chemistry
Leucine (L) → Proline (P) — flexible branched hydrophobic replaced by rigid helix-breaking residue. Same proline-introduction mechanism class as L543P, L402P, L804P.
Position in the protein
C-terminal lumenal domain · position 723 in the ER lumen (pLDDT 83).

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.19 kcal/mol — fold essentially unperturbed. AlphaMissense 0.959 confirms pathogenic mechanism is functional rather than structural.

The mechanism is creation of an unusual Pro-Pro motif at positions 723-724, shifting the local backbone geometry from a Leu-Pro transition to a rigid Pro-Pro segment. Therapeutic strategy: site-directed small molecules at the position 720-724 region, ideally compensating for the geometric shift.

This is one of several proline-introduction variants in the Atlas (L402P, L543P, L723P, L804P). The therapeutic vocabulary across this class is consistent: stabilize local backbone geometry against the introduced proline kink.

Why this matters

L723P creates a Pro-Pro motif rare in folded proteins. The Atlas's neighbor analysis surfaces this directly — PRO724 at 2.5 Å is the next-residue neighbor. The unusual geometry of two adjacent prolines is what distinguishes L723P's mechanism from other proline-introduction variants in the Atlas.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the L723P PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download L723P PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal